Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc.（INDP）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · INDP · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
2
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Indaptus Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
INDP 季度内部人买卖趋势
INDP 内幕交易卖出 · INDP 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · INDP CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
INDP 高管卖出股份 · INDP 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jan 20, 2026 | Ben-Tzvi Avraham Director | Award | 25,000 | — | Form 4 |
| Dec 22, 2025 | Sassi Nir CFO | Award | 26,758 | $54K | Form 4 |
| Dec 22, 2025 | Meckler Jeffrey A Co-Chief Executive Officer · Director | Award | 216,617 | $440K | Form 4 |
| Dec 22, 2025 | Newman Michael James CSO and Director | Award | 52,204 | $106K | Form 4 |
| Dec 22, 2025 | Linscott Walt Addison COO | Award | 54,421 | $110K | Form 4 |
| Jul 27, 2025 | Meckler Jeffrey A CEO · Director | Award | 6,068 | $50K | Form 4 |
| Aug 14, 2023 | Anderson Glen R. 10 percent owner | Purchase | 23,934 | $56K | Form 4 |
| Aug 11, 2023 | Anderson Glen R. 10 percent owner | Purchase | 35,064 | $74K | Form 4 |
| Aug 10, 2023 | Anderson Glen R. 10 percent owner | Purchase | 44,354 | $86K | Form 4 |
| Dec 1, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 500 | $935 | Form 4 |
| Nov 22, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 500 | $915 | Form 4 |
| Mar 2, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 50 | $205 | Form 4 |
| Jan 31, 2022 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | 100 | $465 | Form 4 |
| Jan 31, 2022 | Newman Michael James CSO and Director | Sale | 5,870 | $29K | Form 4 |
| Feb 1, 2022 | Newman Michael James CSO and Director | Sale | 14,130 | $71K | Form 4 |
| Nov 18, 2021 | Meckler Jeffrey A CEO and Director | Purchase | 11,187 | $65K | Form 4 |
Meckler Jeffrey A
Co-Chief Executive Officer · Director
日期
Dec 22
股数
216,617
均价
$2.03
总金额
$440K
Litchev Boyan Vesselinov
Chief Medical Officer
日期
Dec 1
股数
500
均价
$1.87
总金额
$935
Litchev Boyan Vesselinov
Chief Medical Officer
日期
Nov 22
股数
500
均价
$1.83
总金额
$915
Litchev Boyan Vesselinov
Chief Medical Officer
日期
Mar 2
股数
50
均价
$4.09
总金额
$205
Litchev Boyan Vesselinov
Chief Medical Officer
日期
Jan 31
股数
100
均价
$4.65
总金额
$465
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 INDP 内幕交易
INDP 内幕交易
Indaptus Therapeutics, Inc.（INDP）内幕交易数据来源于公司内部人（包括Meckler Jeffrey A (Co-Chief Executive Officer · Director), Ben-Tzvi Avraham (Director), Sassi Nir (CFO)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。INDP内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Indaptus Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
INDP 内幕交易 · 5个问题Indaptus Therapeutics, Inc.（INDP）的内部人包括高管和董事，如Meckler Jeffrey A (Co-Chief Executive Officer · Director), Ben-Tzvi Avraham (Director), Sassi Nir (CFO)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026